Solara Active Pharma Sciences working capital

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
169.51×169.51×197.41×208.07×262.28×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
102.02×102.02×95.97×125.38×129.77×
139.31×139.31×163.63×140.30×136.37×
132.22×132.22×129.75×193.15×255.68×
6.32×−38.23×−5.96×−2.83×16.71×
0.60×0.60×0.56×0.49×0.49×
−20.64×−20.64×394.11×−0.19×−7.03×
0.82×0.82×1.03×−1.14×1.17×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹2,910 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)262.28208.07197.41169.51169.51
Receivable Days (DSO)129.77125.3895.97102.02102.02
Payable Days (DPO)136.37140.30163.63139.31139.31
Cash Conversion Cycle (days)255.68193.15129.75132.22132.22
Working Capital Turnover16.71-2.83-5.96-38.236.32
Asset Turnover0.490.490.560.600.60
Cash Conversion (CFO/Net Income)-7.03-0.19394.11-20.64-20.64
CFO/EBITDA1.17-1.141.030.820.82
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.